The rising incidence of road injuries and joint disorders and development of biocompatible synthetic bone grafts are expected to boost the growth of the bone graft substitute market at a CAGR of 6.52% during the forecast period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Bone Graft Substitute Market” that contains the information from 2019 to 2035.

The bone graft substitute market is estimated to register a CAGR of 6.52% during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Bone graft substitute market - Johnson & Johnson Inc. (US), Baxter (US), Integra Lifesciences Holdings Corporation (US), Orthox Medical Inc. (US), Geistlich Pharma AG (Switzerland), Medtronic (Ireland), AlloSource (Colorado), Zimmer Biomet (US), Stryker (US), Smith & Nephew (US).

Market Highlights

The bone graft substitute market is expected to register a CAGR of 6.52% during the forecast period and is estimated to reach USD 7.83 billion by 2035.

The bone graft substitute market is distinguished by the presence of numerous regional and local players catering to the global bone graft substitute market. Furthermore, the rising incidence of road injuries and joint disorders and development of biocompatible synthetic bone grafts are the major factors driving the growth of the global bone graft substitute market. Additionally, it is also projected that high investment in orthopedic care sector and upsurge in demand for orthopedic procedures among geriatric population will boost the market's growth in the upcoming future.

Access full report @ https://www.marketresearchfuture.com/reports/bone-graft-substitutes-market-1195

Segment Analysis

The bone graft substitute market has been segmented based on type, and application.

On the basis of type, the bone graft substitute market has been segmented into allograft, bone graft substitute, and cell-based matrices. Allografts are further segmented into machined allograft and demineralized bone matrix. Bone graft substitute is further segmented into bone morphogenic proteins (BMP) and synthetic bone grafts. The allograft segment dominated the market in 2024. The allograft segment is projected to be the fastest-growing segment. A bone graft substitute can be defined as a synthetic, inorganic, or biologically organic combination, which can be inserted for the treatment of a bone defect instead of autogenous or allogenous bone. Even though autografts are considered as the ‘gold standard’ for bone grafting procedures, bone graft substitute has become one of the popular routes for administration among many medical users due to the double incision required in the autografting procedure, and the pain associated with the procedure and the post-operative pain on both the sites. Allografts are the logical replacement for autograft. Allograft is harvested from an individual other than the one receiving the graft. It is mostly taken from cadavers that have donated their bone so that it can be used for people who are alive and in need; it is typically sourced from a bone bank. However, there is a high risk of disease transmission while using these allografts for bone grafting as the body from which it is taken may be carrying the disease. Hence, these bones are highly processed and sterilized to reduce the chances of disease transmission. Allografts are segmented into machine allografts and Demineralized Bone Matrix (DBM).

Applications of bone graft substitutes are increasing rapidly as other bone graft types such as autografts and allografts have disadvantages, such as limited availability, site morbidity and pain, and prone to infections. In fact, DBM are used in 50% of allografts performed in the US. The global bone graft substitute market, by application, is segmented into dental, foot & ankle, joint reconstruction, long bone, and spinal fusion. The spinal fusion segment dominated the market in 2020. The spinal fusion segment is projected to be the fastest-growing segment during the study period. Spinal fusion is an extremely important procedure wherein a solid bridge is formed between two vertebral of the spines to stop the movement in that section. It is very important to understand that bone grafts do not directly heal the spinal distress or carry out the spinal fusion. However, bone graft creates an environment for that solid bridge to form. Bone graft provides a foundation for the spine and allows the body to regenerate the bone and fuse the section of the spine. They provide stability to the spine while the body heals itself.

Regional Analysis

On the basis of region, the bone graft substitute market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. Americas held the largest market in 2023, and Asia-Pacific is accounted for the fastest growing region during the forecast period.

The Americas is further segmented into North America and Latin America. North America accounted for the largest market in 2024 and expected to show steady growth. The North American market is further divided into the US and Canada. The largest market share of 81.0% of North Americas is due to several factors such as high volumes of orthopedic surgeries, adoption of bone graft substitutes, and the presence of prominent key players. In addition, the presence of major market players in this region involved in product innovation expansion, expansion, and strategic collaborations, and well-developed healthcare infrastructure are contributing towards the market growth. For instance, in February 2019, Medtronic plc announced approval and launch of Japan's first Grafton Demineralized Bone Matrix (DBM) bone grafting product for spine and orthopedic procedures.

Key Findings of the Study

• 
  

  The bone graft substitute market is expected to reach USD 7.83 billion by 2035, at a CAGR of 6.52% during the forecast period.

  
  


• 
  

  The North America bone graft substitute market accounted largest share in 2024

  
  


• 
  

  Based on type, Allografts segment held the majority share in 2024.

  
  


• 
  

  Johnson & Johnson Inc. (US), Baxter (US), Integra Lifesciences Holdings Corporation (US), Orthox Medical Inc. (US), Geistlich Pharma AG (Switzerland), Medtronic (Ireland), AlloSource (Colorado), Zimmer Biomet (US), Stryker (US), Smith & Nephew (US) are the key market players.